Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

Seoul National University

Status: Completed

Conditions: Breast Cancer

Treatments: Procedure: Neoadjuvant chemotherapy; Procedure: Adjuvant chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06299930

LRR after NACT vs ACT

Details and patient eligibility

About

Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.

Enrollment: 10,328 patients

Sex: Female

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who underwent breast-conserving surgery for invasive breast cancer between 2004 and 2018

Exclusion criteria

• Total mastectomy
• No pre- or postoperative chemotherapy
• No radiation therapy
• Bilateral breast cancer
• Male breast cancer patients
• Secondary breast cancer
• Metachronous or synchronous cancers

Trial design

10,328 participants in 2 patient groups

Neoadjuvant chemotherapy (NACT) group

Description:

Patients who administered chemotherapy before surgery

Treatment:

Procedure: Neoadjuvant chemotherapy

Adjuvant chemotherapy (ACT) group

Description:

Patients who administered chemotherapy after surgery

Treatment:

Procedure: Adjuvant chemotherapy